Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E26.97 EPS (ttm)2.01 Insider Own0.16% Shs Outstand1.63B Perf Week-5.58%
Market Cap88.60B Forward P/E13.85 EPS next Y3.92 Insider Trans0.19% Shs Float1.63B Perf Month-12.06%
Income3.30B PEG2.44 EPS next Q0.91 Inst Own74.40% Short Float0.83% Perf Quarter-2.83%
Sales21.60B P/S4.10 EPS this Y-10.90% Inst Trans0.09% Short Ratio2.27 Perf Half Y6.68%
Book/sh7.54 P/B7.20 EPS next Y8.11% ROA1.10% Target Price61.29 Perf Year-16.04%
Cash/sh3.72 P/C14.58 EPS next 5Y11.07% ROE2.90% 52W Range49.96 - 70.05 Perf YTD-11.39%
Dividend1.60 P/FCF58.17 EPS past 5Y15.30% ROI20.20% 52W High-22.48% Beta0.91
Dividend %2.95% Quick Ratio1.30 Sales past 5Y3.30% Gross Margin70.50% 52W Low8.69% ATR1.37
Employees23700 Current Ratio1.40 Sales Q/Q10.90% Oper. Margin20.90% RSI (14)24.92 Volatility2.43% 2.03%
OptionableYes Debt/Eq0.60 EPS Q/Q-59.30% Profit Margin1.70% Rel Volume2.51 Prev Close55.98
ShortableYes LT Debt/Eq0.46 EarningsOct 25 BMO Payout684.10% Avg Volume5.96M Price54.30
Recom2.50 SMA20-10.68% SMA50-10.46% SMA200-8.29% Volume14,976,590 Change-3.00%
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Oct-20-18 03:15AM  Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer Business Wire
Oct-19-18 04:16PM  Bristol-Myers Squibb Provides Update on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden 10 mut/Mb Business Wire
09:30AM  BMY vs. LLY: Which Stock Should Value Investors Buy Now? Zacks
08:00AM  Today's Research Reports on Trending Tickers: Merck & Co., and Bristol-Myers Squibb ACCESSWIRE
Oct-17-18 06:59AM  Bristol-Myers Squibb to Showcase Immunoscience Research and Biomarker-Guided Treatment Approaches at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting Business Wire
Oct-16-18 01:23PM  Government wants drug companies to disclose prices on TV ads Yahoo Finance Video
Oct-15-18 05:06PM  Health Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners American City Business Journals
08:52AM  Bristol-Myers Reports Disappointing Data From SCLC Study Zacks
08:37AM highlights: Bristol-Myers Squibb, Celanese, Ternium S.A. and Mettler-Toledo International Zacks
Oct-12-18 10:25AM  Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal Zacks
09:30AM  Bristol-Myers Inks Deal and Invests $12 Million in Compugen Zacks
09:28AM  4 Top Stocks to Buy for Superb Earnings Growth Zacks
07:33AM  Bristol-Myers' Opdivo fails to meet lung cancer study goal Reuters
07:14AM  Bristol-Myers' Opdivo fails to meet lung cancer study goal Reuters
07:04AM  Bristol-Myers says trial of small cell lung cancer treatment failed to meet main goal MarketWatch
06:59AM  Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed Small Cell Lung Cancer Business Wire
Oct-11-18 07:32AM  Compugen's stock shoots up after Bristol-Myers to pay 52% premium for equity stake MarketWatch -5.38%
07:00AM  Bristol-Myers to invest in Compugen, collaborate in clinical trials Reuters
06:59AM  Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors PR Newswire
06:59AM  Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors Business Wire
Oct-10-18 05:23PM  Novartis Presents Positive Data on Sickle Cell Disease Drug Zacks
08:51AM  3 Reasons Momentum Stock Investors Will Love Bristol-Myers Squibb (BMY) Zacks
Oct-08-18 11:51AM  AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis Zacks
10:57AM  Stada, buyout funds in race for Bristol-Myers' French business: sources Reuters
09:31AM  The Zacks Analyst Blog Highlights: Home Depot, Bristol-Myers, Costco, Ecolab and Ameriprise Financial Zacks
09:15AM  Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now Zacks
Oct-05-18 04:42PM  Merck Reports Positive Efficacy Data from Phase III HIV Study Zacks
02:16PM  Top Analyst Reports for Home Depot, Bristol-Myers & Costco Zacks
Oct-02-18 11:27AM  Clovis Oncology stock rises 10% after 'breakthrough' designation from FDA MarketWatch
09:32AM  Did Bristol-Myers Squibb Make a Huge Mistake With Nektar? Motley Fool
08:41AM  The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental Zacks
Oct-01-18 12:30PM  Scientists behind game-changing cancer immunotherapies win Nobel medicine prize Reuters
05:51AM  [$$] Cancer researchers win Nobel Medicine Prize Financial Times
05:37AM  Scientists Win Nobel for Key Discoveries in Fighting Cancer Bloomberg
Sep-27-18 09:03AM  Big Pharma Players on Strong Footing Ahead of Q4: 4 Picks Zacks
Sep-26-18 03:21PM  5 Biotech Stocks to Play the Sectors Next Big Trend: NASH InvestorPlace
03:20PM  Novartis to Cut Over 2000 Jobs, Focus on Higher Value Drugs Zacks
Sep-25-18 10:10AM  Why the Earnings Surprise Streak Could Continue for Bristol-Myers (BMY) Zacks
08:29AM  Trump Clinches Trade Deal With South Korea: 6 Winning Picks Zacks
Sep-24-18 10:25AM  AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU Zacks
10:19AM  AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk Zacks
Sep-20-18 07:52PM  Flexible labs, co-working space: Big Pharma is rethinking real estate American City Business Journals
Sep-19-18 06:03PM  Bristol-Myers' MM Drug Empliciti Application Validated by EMA Zacks
09:15AM  Is Bristol-Myers Squibb (BMY) a Great Dividend Play? Zacks
08:48AM  Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff Zacks
Sep-18-18 09:17AM  Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern Zacks
08:13AM  Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth? Zacks
06:59AM  European Medicines Agency Validates Bristol-Myers Squibbs Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma Business Wire
Sep-16-18 06:30PM  Bristol-Myers Squibb's New Psoriasis Drug Has Echoes of Humira
Sep-14-18 10:02AM  Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus Zacks
Sep-13-18 10:54AM  Bristol-Myers Squibb Company (NYSE:BMY) Is Trading At A 23.98% Discount Simply Wall St.
Sep-12-18 04:10PM  Bristol-Myers Squibb Announces Dividend Business Wire
12:06PM  Bristol-Myers plaque psoriasis drug shows promise in mid-stage trial Reuters
11:56AM  Apple under pressure, Tiffany moves higher, Bristol-Myers Squibb dips Yahoo Finance
11:25AM  The Outlook for AstraZeneca Is Positive, But Its Too Early to Pull the Trigger InvestorPlace
09:55AM  Merck's Antibacterial Drug Succeeds in Label Expansion Study Zacks
09:45AM  Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus Zacks
09:44AM  Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug Zacks
07:39AM  Stocks making the biggest move premarket: AAPL, NIO, GILD, TEVA, BMY & more CNBC
02:01AM  Bristol-Myers Squibbs Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial Business Wire
Sep-09-18 06:31AM  Is Bristol-Myers Squibb Company a Buy? Motley Fool
Sep-07-18 09:51AM  The Zacks Analyst Blog Highlights: Caterpillar, D.R. Horton, Bristol-Myers Squibb, athenahealth and BJ's Restaurants Zacks
09:30AM  Why Is Nektar (NKTR) Up 11.2% Since Last Earnings Report? Zacks
Sep-06-18 03:00PM  Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference Business Wire
02:25PM  Here's Why Nektar Therapeutics Jumped 26.4% in August Motley Fool
12:54PM  Novartis to Sell Sandoz's Dermatology Business to Aurobindo Zacks
12:49PM  Biotech Dives After Experimental Lung Cancer Regimen Disappoints Investor's Business Daily
10:09AM  September Bogging You? Look at the Best 9-Month Run Instead Zacks
06:59AM  Bristol-Myers Squibb to Announce Results for Third Quarter 2018 on October 25 Business Wire
Sep-05-18 06:07PM  J&J Submits NDA to the FDA for Depression Drug in Adults Zacks
04:17PM  This Biotech Got A Bullish Pop On Its Experimental Cancer Regimen Investor's Business Daily
12:37PM  Why Bristol-Myers Squibb Is a Great Dividend Stock InvestorPlace
09:11AM  The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Cleveland-Cliffs, Callaway Golf, SkyWest and Vishay Intertechnology Zacks
06:59AM  Bristol-Myers Squibb Kicks Off Coast 2 Coast 4 Cancer Ride to Fundraise for the V Foundation for Cancer Research Business Wire
Sep-04-18 02:27PM  5 Top Stocks to Challenge a Notorious September InvestorPlace
10:08AM  AstraZeneca Up This Year So Far on Favorable Pipeline Updates Zacks
09:34AM  The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Qualcomm, Citigroup, Diageo and Anthem Zacks
07:56AM  5 Top Stocks to Challenge a Notorious September Zacks
Sep-03-18 09:15AM  Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Zacks
Aug-31-18 03:53PM  Merck (MRK) Receives FDA Approval for Two HIV Medicines Zacks
01:46PM  Top Stock Reports for Bristol-Myers, Qualcomm & Citigroup Zacks
08:39AM  4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline Zacks
Aug-30-18 08:54AM  Is Beaten-Down Exelixis, Inc. a Buy Now? Motley Fool
06:59AM  U.S. Food and Drug Administration Accepts Bristol-Myers Squibbs Application for Sprycel (dasatinib) in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Business Wire
Aug-29-18 09:43AM  Novartis' Tafinlar/Mekinist Combo Gets EU Nod for 3rd Disease Zacks
09:30AM  Pfizer Stock Up This Year So Far: What's Going in its Favor? Zacks
Aug-28-18 09:00AM  Bristol-Myers Squibb Appoints Christopher Boerner Executive Vice President and Chief Commercial Officer Business Wire
Aug-27-18 11:30AM  Bristol-Myer Stock May Jump 9% on Rising Forecasts Investopedia
08:13AM  The Zacks Analyst Blog Highlights: Amazon, Microsoft, Apple, Bristol-Myers and Celgene Zacks
Aug-24-18 09:51AM  R&D Spending Hits the Fastest Pace in 12 Years: Top 5 Winners Zacks
09:44AM  Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review Zacks
08:54AM  Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs Zacks
Aug-23-18 11:00AM  Pfizer Amends Xtandi Study Protocols to Speed Up Completion Zacks
10:04AM  J&J to Appeal as Judge Confirms Jury Order in Talc Case Zacks
07:52AM  Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio Zacks
06:59AM  U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibbs Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Business Wire
Aug-22-18 06:17PM  Bill Nygren's Top 3 Buys in 2nd Quarter
11:42AM  Bristol-Myers Is Confronting Overhead Resistance and a Lack of Aggressive Buying
09:45AM  Allergan Falls on FDA's Rejection of Uterine Fibroids Drug Zacks
Aug-21-18 07:12AM  The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed Motley Fool
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; and Compugen Ltd.; and Tsinghua University, as well as a research partnership with Sirenas. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.005920592Oct 04 04:56 PM
Dubow AdamChief Compliance & Ethics OffiSep 03Option Exercise0.00797015,495Sep 05 04:49 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064104,057Sep 05 04:49 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510050,168Aug 03 05:05 PM
Biondi PaulSVP, Head of Strategy & BDJul 01Option Exercise0.001,46101,461Jul 03 09:24 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400292,822May 08 05:05 PM
Paliwal Dinesh CDirectorApr 30Buy52.404,770249,9488,027May 02 04:05 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0012,367018,267Apr 05 04:37 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00219,2110333,970Mar 13 04:56 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0036,044075,370Mar 13 04:56 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,043086,932Mar 13 04:56 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0034,681053,132Mar 13 04:57 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0039,235062,028Mar 13 04:55 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.004,40704,456Mar 13 04:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0091,3180363,739Mar 13 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,2750136,441Mar 13 04:54 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0068,8960488,677Mar 13 04:54 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 23Option Exercise22.1437,460829,364302,348Feb 27 04:45 PM
Samuels Theodore R. IIDirectorDec 15Buy62.304,000249,18722,000Dec 18 04:21 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerDec 12Sale63.245,300335,1729,251Dec 13 05:31 PM
LEUNG SANDRAEVP, General CounselDec 04Option Exercise22.14156,5823,466,725584,373Dec 05 06:15 PM
LEUNG SANDRAEVP, General CounselDec 04Sale63.37156,5829,922,601427,791Dec 05 06:15 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010267,770Dec 05 06:15 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494068,166Nov 03 04:32 PM